AUTHOR=Müller Hannes , Szalkiewicz Philipp , Benedikt Peter , Ratschiller Thomas , Schachner Bruno , Schröckenstein Sophie , Zierer Andreas 

TITLE=Single-center real-world data and technical considerations from 100 consecutive patients treated with the Perceval aortic bioprosthesis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=11

YEAR=2024

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1417617

DOI=10.3389/fcvm.2024.1417617

ISSN=2297-055X

ABSTRACT=<sec><title>Objectives</title><p>Although the Perceval sutureless aortic valve bioprosthesis presents a feasible alternative to conventional aortic valve prostheses, the extent of its applicability with respect to technical considerations for a real-world patient collective is still under debate.</p></sec><sec><title>Methods</title><p>One hundred patients received the Perceval prosthesis [males: 59; age: 72.5 (7.3–79) years] between December 2015 and February 2023 [EuroSCORE II: 2.8 (1.7–5.4)] for an aortic valve replacement (AVR), with additional concomitant procedures, for underlying severe aortic valve stenosis [<italic>n</italic> = 93 (93)], endocarditis [<italic>n</italic> = 5 (5)], and redo AVR [<italic>n</italic> = 7 (7)] including a prior surgical AVR [<italic>n </italic>=<italic> </italic>4 (4)] and a failed transcatheter aortic valve implantation [<italic>n </italic>=<italic> </italic>3 (3)]. Surgery was conducted primarily by median sternotomy [<italic>n </italic>=<italic> </italic>71 (71)] and, alternatively, by the upper hemisternotomy approach [<italic>n</italic> = 29 (29)].</p></sec><sec><title>Results</title><p>Over a median follow-up time of 36.5 (16.5–53) months, eight patients (8%) underwent postoperative pacemaker implantation, with five (5%) due to high-grade atrioventricular block, while nine patients experienced a stroke (9%). The median values of maximum and mean gradients across all valve sizes were 22 (18–27.5) mmHg and 10 (13–18) mmHg, respectively. Two patients (2%) had moderate and one (1%) had severe paravalvular leakage, with the latter presenting the only case of underlying valve migration and induced redo AVR with valve explantation 2 days following initial surgery. Thirty-day mortality (and overall mortality) was 5% and 26%, respectively.</p></sec><sec><title>Conclusion</title><p>The implantation of the Perceval bioprosthesis is feasible for a variety of indications, with excellent hemodynamic results and low complication rates in a real-world high-risk patient collective.</p></sec>